Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
ФГБУ «Национальный медицинский исследовательский центр гематологии» Минздрава России. 125167, Россия, Москва, Новый Зыковский пр-д, д. 4 dvyb@yandex.ru
Список исп. литературыСкрыть список 1. Davidson PW. Hysterical dysphemia. Am J Psychiatry 1964; 121: 395–7. 2. Weddington WW. Psychogenic nausea and vomiting associated with termination of cancer chemotherapy. Psychother Psychosomatics 1982; 37: 129–36. 3. Nesse RM, Carli T, Curtis GC, Kleinman PD. Pseudohallucinations in cancer chemotherapy patients. Am J Psychiatry 1983; 140 (4): 483–5. 4. Cella DF, Pratt A, Holland JC. Persistent anticipatory nausea, vomiting, and anxiety in cured Hodgkin’s disease patients after completion of chemotherapy. Am J Psychiatry 1986; 143 (5): 641–3. 5. Nerenz DR, Leventhal H, Easterling DV, Love RR. Anxiety and drug taste as predictors of anticipatory nausea in cancer chemotherapy. J Clin Oncol 1986; 4 (2): 224–33. 6. Kawiecka-Dziembowska B, Borkowska A, Zurawski B et al. Ocena temperamentu [The assessment of temperament, quality of life and intensity of depressive symptoms in patients with Hodgkin’s disease in different stages of the illness]. Psychiatr Pol 2005; 39 (4): 679–90. 7. Isa A, Miles J, Emslie G, Coffey DBJ. Depression Pharmacotherapy in an Adolescent with Hodgkin’s Lymphoma J. Child Adolesc. Psychopharmacol 2012; 22 (4): 316–9. 8. Выборных Д.Э. Психические расстройства у больных с заболеваниями системы крови (типология, эпидемиология, терапия). Дис. … д-ра мед. наук. 2012. / Vybornykh D.E. Psikhicheskiye rasstroystva u bol'nykh s zabolevaniyami sistemy krovi (tipologiya, epidemiologiya, terapiya). Dis. … d-ra med. nauk. 2012. [in Russian] 9. Выборных Д.Э., Олексенко Л.В., Хрущев С.О. и др. Структура психических расстройств у больных лимфогранулематозом. Психическое здоровье человека XXI века. Сб. науч. статей по материалам Конгресса. 2016; с. 294–6. / Vybornykh D.E., Oleksenko L.V., Khrushchev S.O. i dr. Struktura psikhicheskikh rasstroystv u bol'nykh limfogranulematozom. Psikhicheskoye zdorov'ye cheloveka XXI veka. Sb. nauch. statey po materialam Kongressa. 2016; s. 294–6. [in Russian] 10. Vybornykh D, Olexenko L, Khrushchev S et al. Mental disorders in Hodgkin’s disease patients. Haematologica 2016; 101 (S5): 72. 11. Олексенко Л.В., Выборных Д.Э. Соматогенные психозы при лимфоме Ходжкина. Психические расстройства в общей медицине. 2017. 1–2: 19–23. / Olexenko L.V., Vybornykh D.E. Somatogenic psychoses in Hodgkin's lymphoma. Mental Disorders in General Medicine. 2017; 1: 19–23. [in Russian] 12. Devlen J, Maguire, Phillips P et al. Psychological problems associated with diagnosis and treatment of lymphomas. I: Retrospective study. Br Med J (Clin Res Ed) 1987; 295 (17): 953–4. 13. Dos Santos MJ, Pimentel P, Monteiro JM et al. Psychiatric disorders in hospitalized patients with hematologic neoplasms. Acta Med Port 1991; 4 (1): 5–8. 14. Loge JH, Abrahamsen AF, Ekeberg O et al. Psychological distress after cancer cure: a survey of 459 Hodgkin’s disease survivors. Br J Cancer 1997; 76 (6): 791–6. 15. Stark D, Kiely M, Smith A et al. Anxiety disorders in cancer patients: Their nature, associations, and relation to quality of life. J Clin Oncol 2002; 20: 3137–48. 16. Lavoie JC, Connors JM, Phillips GL et al. High-dose chemotherapy and autologous stem cell transplantation for primary refractory or relapsed Hodgkin lymphoma: Long-term outcome in the first 100 patients treated in Vancouver. Blood 2005; 106: 1473–8. 17. Oerlemans S, Mols F, Nijziel MR et al. The course of anxiety and depression for patients with Hodgkin’s lymphoma or diffuse large B cell lymphoma: a longitudinal study of the PROFILES registry. J Cancer Surviv 2014; 8 (4): 555–64. 18. Daniels LA, Oerlemans, S, Krol ADG et al. Chronic fatigue in Hodgkin lymphoma survivors and associations with anxiety, depression and comorbidity. Br J Cancer 2014; 110: 868–74. 19. Reesal RT, Bajramovic H, Mai F. Anticipatory nausea and vomiting: a form of chemotherapy phobia? Can J Psychiatry 1990; 35 (1): 80–2. 20. Vybornykh DE, Olexenko LV, Savchenko VG. Psychohematology. Attempt to Summarise. Int J Hematol Res 2016; 2 (1): 103–14. 21. Nesse RM, Carli T, Curtis GC, Kleinman PD. Pseudohallucinations in cancer chemotherapy patients. Am J Psychiatry 1983; 140: 483–5. 22. Смулевич А.Б., Иванов С.В., Бескова Д.А., Шафигуллин М.Р. Нозогенные реакции у больных раком желудка. Психические расстройства в общей медицине. 2007. 3: 4–10. / Smulevich A.B., Ivanov S.V., Beskova D.A., Shafigullin M.R. Nozogennyye reaktsii u bol'nykh rakom zheludka. Mental Disorders in General Medicine. 2007. 3: 4–10. [in Russian] 23. Самушия М.А., Мустафина Е.А. Нозогении (психогенные реакции) у женщин со злокачественными опухолями органов репродуктивной системы Психические расстройства в общей медицине. 2007. 2: 11–6. / Samushiya M.A., Mustafina Ye.A. Nozogenii (psikhogennyye reaktsii) u zhenshchin so zlokachestvennymi opukholyami organov reproduktivnoy sistemy. Mental Disorders in General Medicine. 2007. 2: 11–6. [in Russian] 24. Скрябин Д.C. Нозогенные реакции при раке поджелудочной железы. Психические расстройства в общей медицине. 2009. 4: 9–16. / Skryabin D.C. Nozogennyye reaktsii pri rake podzheludochnoy zhelezy. Mental Disorders in General Medicine. 2009. 4: 9–16. [in Russian] 25. Выборных Д.Э. Психогематология. М.: Практическая медицина, 2014. / Vybornykh D.E. Psikhogematologiya. M.: Prakticheskaya meditsina, 2014. [in Russian] 26. Выборных Д.Э., Олексенко Л.В., Федорова С.Ю., Хрущев С.О. Психические расстройства в пространстве заболеваний системы крови (типология и терапия). Архивъ внутренней медицины. 2016; S1: 34. / Vybornykh D.E., Oleksenko L.V., Fedorova S.YU., Khrushchev S.O. Psikhicheskiye rasstroystva v prostranstve zabolevaniy sistemy krovi (tipologiya i terapiya). Arkhiv" vnutrenney meditsiny. 2016; S1: 34. [in Russian] 27. Смулевич А.Б., Иванов С.В., Мясникова Л.К. и др. Диссоциативные расстройства в онкологии: психопатология, аспекты коморбидности с расстройствами личности. Психические расстройства в общей медицине. 2014; 3–4: 4–14. / Smulevich A.B., Ivanov S.V., Myasnikova L.K. i dr. Dissotsiativnyye rasstroystva v onkologii: psikhopatologiya, aspekty komorbidnosti s rasstroystvami lichnosti. Mental Disorders in General Medicine. 2014; 3–4: 4–14. [in Russian] 28. Janet P. L’autosomatism psychologique. Paris: Alcan, 1889. 29. Wernike C. Grundriss der Psychiatrie in klinischen Vorlesungen. Leipzig: Thieme, 1906. 30. Stransky E. Die paranoiden Erkrankungen. Z ges Neurol Psychiat 1913; 18: 386–416. 31. Kretschmer E. Der sensitive Beziehungwahn. Aufl 4. Berlin: Springer-Verlag, 1918. 32. Pilowsky I. Abnormal illness behavior (dysnosognosia). Psychother Psychosom 1986; 46 (1–2): 76–84. 33. Выборных Д.Э., Хрущев С.О. Аффективные расстройства с суицидальными тенденциями у пациентов с заболеваниями системы крови. Общественное психическое здоровье: настоящее и будущее. Сб. материалов VI Национального конгресса по социальной психиатрии и наркологии. 2016: 88–9. / Vybornykh D.E., Khrushchev S.O. Affektivnyye rasstroystva s suitsidal'nymi tendentsiyami u patsiyentov s zabolevaniyami sistemy krovi. Obshchestvennoye psikhicheskoye zdorov'ye: nastoyashcheye i budushcheye. Sb. materialov VI Natsional'nogo kongressa po sotsial'noy psikhiatrii i narkologii. 2016: 88–9. [in Russian] 34. Häfner H. Die existentielle Depression. Arch Psychiatr Nervenkrankheiten Ver Zeitschrift Gesamte Neurol Psychiatr 1954; 191 (5): 351–64. 35. Выборных Д.Э., Моисеева Т.Н., Габеева Н.В., Савченко В.Г. Нарушения терапевтического сотрудничества (non-compliance) у пациентов с лимфогранулематозом. Психические расстройства в общей медицине. 2009; 1: 32–4. / Vybornykh D.E., Moiseyeva T.N., Gabeyeva N.V., Savchenko V.G. Narusheniya terapevticheskogo sotrudnichestva (non-compliance) u patsiyentov s limfogranulematozom. Mental Disorders in General Medicine. 2009; 1: 32–4. [in Russian] 36. Смулевич А.Б., Романов Д.В., Мухорина А.К., Атаджыкова Ю.А. Феномен «фершробен» при шизофрении и расстройствах шизофренического спектра (типологическая дифференциация). Журн. неврологии и психиатрии им. С.С.Корсакова. 2017; 117 (1): 5–16. / Smulevich A.B., Romanov D.V., Mukhorina A.K., Atadzhykova Yu.A. Fenomen «fershroben» pri shizofrenii i rasstroystvakh shizofrenicheskogo spektra (tipologicheskaya differentsiatsiya). Zhurn. nevrologii i psikhiatrii im. S.S.Korsakova. 2017; 117 (1): 5–16. [in Russian] 37. Иванов С.В., Петелин Д.С. Типология нозогенных реакций с явлениями аутоагрессии (феномен откладывания) при злокачественных новообразованиях. Психические расстройства в общей медицине. 2016. 3: 17–25. / Ivanov S.V., Petelin D.S. Typology of self-injuring nozogenic reactions (delay phenomenon) in malignant tumors. Mental Disorders in General Medicine. 2016; 3: 17–25. [in Russian] 38. Pack GT, Gallo JS. The Culpability for Delay in the Treatment of Cancer. Am J Cancer 1938; 33: 443–63. 39. Буренина Н.И. Психопатологическая дифференциация патологических телесных сенсаций. Журн. неврологии и психиатрии им. С.С.Корсакова. 1997; 5: 22–6. / Burenina N.I. Psikhopatologicheskaya differentsiatsiya patologicheskikh telesnykh sensatsiy. Zhurn. nevrologii i psikhiatrii im. S.S.Korsakova. 1997; 5: 22–6. [in Russian] 40. Shontz FC. Body image and its disorders. Int J Psychiatry Med 1974; 5 (4): 461–72. 41. Kayilioğlu H, Kocak U, Kan Karaer D et al. Association of CYP3A5 Expression and Vincristine Neurotoxicity in Pediatric Malignancies in Turkish Population. J Pediatr Hematol Oncol 2017; 39 (6): 458–62. 42. Panneerselvam S, Yesudhas D, Durai P et al. A Combined Molecular Docking/Dynamics Approach to Probe the Binding Mode of Cancer Drugs with Cytochrome P450 3A4. Molecules 2015; 20 (8): 14915–35. 43. Mach CM, Fugii H, Wakame K, Smith J. Evaluation of active hexose correlated compound hepatic metabolism and potential for drug interactions with chemotherapy agents. J Soc Integr Oncol 2008; 6 (3): 105–9. 44. Cordova E, Morganti L, Odzak A et al. Severe hypokalemia due to a possible drug-drug interaction between vinblastine and antiretrovirals in a HIV-infected patient with Hodgkin’s lymphoma. Int J STD AIDS 2017: 956462417703026. 45. Lewis BC, Korprasertthaworn P, Miners JO. Impaired dacarbazine activation and 7-ethoxyresorufin deethylation in vitro by polymorphic variants of CYP1A1 and CYP1A2 Pharmacogenet. Genomics 2016; 26 (10): 453–61. 46. Tulsyan S, Agarwal G, Lal P, Mittal B. Significant role of CYP450 genetic variants in cyclophosphamide based breast cancer treatment outcomes: a multi-analytical strategy. Clin Chim Acta 2014; 434: 21–8. 47. Joerger M. Covariate pharmacokinetic model building in oncology and its potential clinical relevance. AAPS J 2012; 14 (1): 119–32. 48. Alonso S, Su M, Jones JW et al. Human bone marrow niche chemoprotection mediated by cytochrome P450 enzymes. Oncotarget 2015; 6 (17): 14905–12. 49. Wahlang B, Falkner KC, Cave MC, Prough RA. Role of Cytochrome P450 Monooxygenase in Carcinogen and Chemotherapeutic Drug Metabolism. Adv Pharmacol 2015; 74: 1–33. 50. Busse KH, Formentini E, Alfaro RM et al. Influence of Antiretroviral Drugs on the Pharmacokinetics of Prednisolone in HIV-Infected Individuals. JAIDS J Acquir Immune Defic Syndr 2008; 48 (5): 561–6. 51. Johnson B, Adams L, Lu E et al. Impact of casopitant, a novel NK-1 antagonist, on the pharmacokinetics of ondansetron and dexamethasone Support. Care Cancer 2009; 17 (9): 1177–85. 52. Petros WP, Hopkins PJ, Spruill S et al. Associations between drug metabolism genotype, chemotherapy pharmacokinetics, and overall survival in patients with breast cancer. J Clin Oncol 2005; 23 (25): 6117–25. 53. Quintanilha JCF, de Sousa VM, Visacri MB et al. Involvement of cytochrome P450 in cisplatin treatment: implications for toxicity. Cancer Chemother Pharmacol 2017; 80 (2): 223–33. 54. McGrane IR, Loveland JG, de Leon J. Possible Oxcarbazepine Inductive Effects on Aripiprazole Metabolism: A Case Report. J Pharm Pract 2017: 897190017710523. 55. Быков Ю.В., Беккер Р.А. Сульпирид в терапии тревожных расстройств и тревожной симптоматики в рамках иных расстройств (обзор литературы). Психиатрия и психофармакотерапия им. П.Б.Ганнушкина. 2016; 18 (5): 29–37. / Bykov Yu.V., Bekker R.A. Effectiveness of an atypical antipsychotic sulpiride in the therapy of various anxiety disorders and anxiety symptoms present in other disorders (a review of the literature). Psychiatry and Psychopharmacotherapy (P.B.Gannushkin Journal). 2016; 18 (5): 29–37. [in Russian] 56. Lisbeth P, Vincent H, Kristof M et al. Genotype and co-medication dependent CYP2D6 metabolic activity: effects on serum concentrations of aripiprazole, haloperidol, risperidone, paliperidone and zuclopenthixol. Eur J Clin Pharmacol 2016; 72 (2): 175–84. 57. Okubo M, Narita M, Murayama N et al. Individual differences in in vitro and in vivo metabolic clearances of the antipsychotic drug olanzapine from non-smoking and smoking Japanese subjects genotyped for cytochrome P4502D6 and flavincontaining monooxygenase 3. Hum Psychopharmacol 2016; 31 (2): 83–92. 58. Luk S, Atayee RS, Ma JD, Best BM. Urinary diazepam metabolite distribution in a chronic pain population. J Anal Toxicol 2014; 38 (3): 135–42. 59. Vrzal R, Kubesova K, Pavek P, Dvorak Z. Benzodiazepines medazepam and midazolam are activators of pregnane X receptor and weak inducers of CYP3A4: investigation in primary cultures of human hepatocytes and hepatocarcinoma cell lines. Toxicol Lett 2010; 193 (2): 183–8. 60. Малин Д.И. Побочное действие психотропных средств. М., 2000. / Malin D.I. Pobochnoye deystviye psikhotropnykh sredstv. M., 2000. [in Russian] 61. He Q, Yuan Z, Liu Y et al. Correlation between cytochrome P450 2C19 genetic polymorphism and treatment response to escitalopram in panic disorder. Pharmacogenet Genomics 2017; 27 (8): 279–84. 62. Yuce-Artun N, Baskak B, Ozel-Kizil ET et al. Influence of CYP2B6 and CYP2C19 polymorphisms on sertraline metabolism in major depression patients. Int J Clin Pharm 2016; 38 (2): 388–94. 63. Tang L, Ye L, Lv C et al. Involvement of CYP3A4/5 and CYP2D6 in the metabolism of aconitine using human liver microsomes and recombinant CYP450 enzymes. Toxicol Lett 2011; 202 (1): 47–54. 64. Lobello KW, Preskorn SH, Guico-Pabia CJ et al. Cytochrome P450 2D6 phenotype predicts antidepressant efficacy of venlafaxine: a secondary analysis of 4 studies in major depressive disorder. J Clin Psychiatry 2010; 71 (11): 1482–7. 65. Irarrázaval OME, Gaete GL. Antidepressants agents in breast cancer patients using tamoxifen: review of basic and clinical evidence. Rev Med Chil 2016; 144 (10): 1326–35. 66. Giri P, Naidu S, Patel N et al. Evaluation of In Vitro Cytochrome P450 Inhibition and In Vitro Fate of Structurally Diverse N-Oxide Metabolites: Case Studies with Clozapine, Levofloxacin, Roflumilast, Voriconazole and Zopiclone. Eur J Drug Metab Pharmacokinet 2017; 42 (4): 677–88. 67. Vybornykh D, Khrushchev S, Olexenko L et al. Coping strategies in patients with hematological malignancies. Psycho-Oncology 2016; 25 (S3): 176. 68. Kubacka-Jasiecka D. Problematyka lęku i zmaganie się z lękiem w chorobie nowotworowej Zmagając się z chorobą nowotworową. Kraków: Wydawnictwo Uniwersytetu Jagiellońskiego, 1999. 69. Spiegel D, Cardeña E. Disintegrated experience: the dissociative disorders revisited. J Abnorm Psychol 1991; 100 (3): 366–78. 70. Van der Hart O, Nijenhuis E, Steele K, Brown D. Trauma-related dissociation: conceptual clarity lost and found. Aust N Z J Psychiatry 2004; 38 (11–12): 906–14. 71. Holmes EA, Brown RJ, Mansell W et al. Are there two qualitatively distinct forms of dissociation? A review and some clinical implications. Clin Psychol Rev 2005; 25 (1): 1–23. 72. Allen JG. Traumatic relationships and serious mental disorders. New York, 2001. 73. Brown RJ. Different types of “dissociation” have different psychological mechanisms. J Trauma Dis 2006; 7 (4): 7–28.